Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
LEXINGTON, Mass and AMSTERDAM, the Netherlands, Aug. 24, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will participate in a gene therapy panel discussion and host investor meetings during the Citi Healthcare Conference held in Boston from September 5-7, 2017.
Matt Kapusta, chief executive officer of uniQure, will participate on the analyst-moderated panel entitled, “Gene-Therapy Manufacturing and Regulatory – Challenges and Opportunities” on Thursday, September 7, 2017 at 11:00 am EDT. A live webcast of the panel discussion can be accessed through the link displayed in the Investor Section of the uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: For Investors: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected] For Media: Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected]
